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Financial conflicts of interest are common in clinical research. For example, in a cohort of oncology 
drug trials, industry funded 44% of trials while 69% of authors declared conflicts of interest [1]. For a 
drug company, the financial impact of a positive pivotal trial can be considerable. For example, the 
mean stock price of the companies funding 23 positive pivotal oncology trials increased by 14% after 
disclosure of the results [2]. Several dramatic cases of biased industry trials have been widely debated 
[3]. These often involved selective reporting of outcomes and gift/ghost authorships. Other cases 
involved companies intimidating authors of independent investigations [4].  
 
Conflicts of interests do not necessarily cause biased trial results but create the risk thereof. 
Unfortunately, our knowledge of what factors affect that risk, and to what extent, is incomplete. In 
this editorial we address the intersection between financial conflicts of interest, including industry 
funding, and bias in clinical research. 
 
A conflict of interest is typically defined as: “a set of circumstances that creates a risk that 
professional judgment or actions regarding a primary interest will be unduly influenced by a 
secondary interest” [5]. In clinical research, the primary interest is to conduct a relevant and unbiased 
investigation. Secondary interest typically relates to financial relations. Financial conflicts of interest 
arise when clinical investigators have relationships with the company that manufactures the drug or 
device subject of the investigation. Those relationships could be in the form of study funding; 
monetary payments, consultancies, share ownership, or advisory board membership; or when 
investigators stand to gain financially from a study result in other ways, e.g. patents. 
 
 Bias is a systematic error in the results of individual studies or their synthesis. Bias in this technical 
and narrow sense should be clearly distinguished from its broader meanings of prejudiced 
investigator motives, and “problematic” investigation. 
When addressing the risk of bias in a clinical study it may be challenging to determine which aspects 
of a trial should be regarded as indicators of bias, e.g., whether conflict of interests should be 
considered. The widely used Cochrane risk of bias tool for randomized trials addresses this by 
including only six mechanistically defined core bias domains: generation of allocation sequence, 
concealment of allocation sequence, blinding of participants and treatment providers, blinding of 
outcome assessors, attrition, and publication bias. Financial conflicts of interests is not included 
(though this has been debated) as it is not regarded a mechanism through which biases are 
introduced into trials, but a motivation behind them. The intention is to pick up any bias associated 
with conflict of interest indirectly through one of the outlined mechanisms.  
A key question is whether trials with and without financial conflicts of interests reach different results. 
A systematic review of 75 such comparisons reported that industry funding was associated with 
positive trial conclusions and more frequent statistically significant results, but could give no clear 
answer to whether the size of the estimated treatment effects differed, and found no association with 
the assessment of conventional bias domains [6]. However, confounding in such comparisons is 
considerable, as the result of trials may differ for many reasons other than funding source (e.g. choice 
of study comparator or outcome). One included study minimized this risk of confounding by sampling 
comparable trials from meta-analyses. It reproduced the general association with positive conclusions 
and no clear association with size of estimated treatment effects [7]. A similar pattern was found in 
studies of financial conflicts of interest in systematic reviews [8]. So, it appears that commercial 
funding is robustly associated with favorable conclusions but less so with estimated treatment effects.  
Industry funded trials often differ from non-industry funded ones. An industry funded trial is often 
large, participants are often carefully selected, placebo is often used as comparator, and short-time 
surrogate outcomes are frequently used [9,10]. In some cases industry trials or outcomes may not be 
published if deemed commercially unfavorable. Trial registration and decades of debate about 
publication bias have improved matters to some degree, but lack of transparency and incomplete 
reporting of trials is still a significant problem [10,11]. Furthermore, trial results are often over-
interpreted and spin in conclusions is frequent [12]. Such trials, if fully reported, may not be biased in 
the strict sense that their estimated treatment effect is wrong, but they are often problematic in the 
broader sense that results do not include the most relevant outcomes or may not be directly 
transferable to the typical patient.  
 
Besides industry funding, individual and institiutional financial conflicts of interest of clinical 
investigators, as well as their non-financial conflicts may also unduly influence the planning, conduct 
and reporting of their studies. Financial ties of principal investigators seem to be independently 
associated with positive clinical trial results [13]. In addition, financial conflicts of interest may bias 
the dissemination of study findings, e.g., when these investigators display strong advocacy on social 
 media. Moreover, conflicted investigators may inappropriately favor industry interests when acting as 
content experts on panels of regulatory agencies or clinical practice guidelines [14].  
 
The most common approach to managing conflicts of interest of clinical investigators is the public 
reporting of relevant conflicts. Unfortunately, there is evidence of high rates of underreporting of 
financial conflicts of interest [15]. In addition, there is concern that simple public disclosure, 
particularly in the context of guideline panels, is not enough. Problems related to conflicts of interest 
in trials may be especially concerning in systematic reviews where several trials are combined. To 
counter this, a tool to address conflicts of interest in trials (TACIT) is under development under the 
auspices of the Cochrane Bias Methods Group. 
 
The field of clinical research needs to improve its approaches to identifying and managing financial 
conflicts of interest. This includes the need to develop methods and tools to verify the accuracy and 
completeness of declared financial conflicts of interest; to further assess the extent of bias associated 
with a financial relationship; and to minimize the risk of bias associated with the conflicts of interest 
of investigators. 
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